Back to results
US 2003/0152514 A1Published application
Methods for using anti-MUC18 antibodies
AssigneeAbgenix, Inc.
InventorJean Gudas
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.
Claims17
A method of inhibiting cell proliferation associated with the expression of MUC18 tumor antigen comprising:
- providing a monoclonal antibody comprising a heavy chain amino acid, wherein said antibody has an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 1,5 9, 13, 17, 21, 25, 29, 33 and 37, and wherein said monoclonal antibody binds MUC18;
- contacting cells expressing MUC18 with an effective amount of said antibody;
- and
- incubating said cells and said antibody, wherein said incubation results in inhibited proliferation of said cells.
2 more elements
A method of inhibiting cell proliferation associated with the expression of MUC18 tumor antigen comprising:
- providing a monoclonal antibody comprising a light chain amino acid, wherein said antibody has an amino acid sequence selected from the group consisting of:
- SEQ ID NOs:
- 2, 6, 10, 14, 18, 22, 26, 30, 34 and 38, and wherein said monoclonal antibody binds MUC18;
- contacting cells expressing MUC18 with an effective amount of said antibody;
- and
- incubating said cells and said antibody, wherein said incubation results in inhibited proliferation of said cells.
3 more elements
The method of claim 13, wherein the cytotoxic agent is ricin.
Dependencies are inferred from the claim text.